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ABSTRACT
Objective To identify factors predictive of relapse risk 
and disability in myelin oligodendrocyte glycoprotein 
associated disease (MOGAD).
Setting Patients were seen by the neuromyelitis optica 
spectrum disorders (NMOSD) service in Liverpool, UK, a 
national referral centre for adult patients with MOGAD, 
NMOSD and related conditions.
Participants Patients with MOGAD=76 from England, 
Northern Ireland and Scotland were included in this cohort 
study.
Results Relapsing disease was observed in 55% (42/76) 
of cases. Steroid treatment >1 month (OR 0.2, 95% CI 0.05 
to 0.80; p=0.022), transverse myelitis (TM) at first attack 
(OR 0.03, 95% CI 0.004 to 0.23; p=0.001) and male sex 
(OR 0.16, 95% CI 0.04 to 0.68; p=0.014) were associated 
with monophasic disease (area under the curve=0.85). 
Male sex (HR 0.46, 95% CI 0.24 to 0.89; p=0.011) and TM 
at disease onset (HR 0.42, 95% CI 0.22 to 0.82; p=0.011) 
were also associated with an increased latency to first 
relapse. 45% (32/71) of patients became MOG- antibody 
negative and in relapsing patients negative seroconversion 
was associated with a lower relapse risk (relative risk 0.11 
95% CI 0.05 to 0.26; p<0.001). No specific factors were 
predictive of visual or overall disability.
Conclusions Male patients with spinal cord involvement 
at disease onset have a lower risk of relapsing disease 
and longer latency to first relapse. Steroid treatment for 
at least 1 month at first attack was also associated with 
a monophasic disease course. MOG- antibody negative 
seroconversion was associated with a lower risk of relapse 
and may help inform treatment decisions and duration.
INTRODUCTION
Myelin oligodendrocyte glycoprotein anti-
body associated disease (MOGAD) is asso-
ciated with central nervous system (CNS) 
inflammation, typically acute disseminated 
encephalomyelitis, optic neuritis (ON), trans-
verse myelitis (TM) and brainstem inflamma-
tion.1–7 In retrospective studies, a relapsing 
disease course has been reported in 27%–80% 
of patients, which may over- report the propor-
tion of relapsing patients by virtue of differen-
tial follow- up of monophasic versus relapsing 
patients.1–5 Indeed in two studies using inci-
dent cohorts, rates of relapsing disease were 
at the lower end (27%–36%).1 2 Although 
MOGAD is associated with a better prognosis 
compared with neuromyelitis optica spec-
trum disorder (NMOSD), persistent visual, 
motor or sphincter disturbances have been 
reported.1 7 These studies collectively support 
the presence of a subgroup of patients with 
MOGAD with lower risk of relapse and 
minimal if any long- term disability. This 
has understandably led to equipoise among 
international experts on when to introduce 
chronic immunotherapy and the duration of 
treatment.8 Identifying prognostic factors for 
risk of (1) early relapse, (2) any relapse and 




All patients were seen by the NMOSD UK 
service at the Walton Centre NHS Foundation 
Trust in Liverpool, UK, a national referral 
centre for adult patients with NMOSD, 
MOGAD and other non- multiple sclerosis 
atypical CNS inflammatory/demyelinating 
syndromes. Patients from England, Northern 
Ireland and Scotland were included.
Between January 2010 and January 
2020, patients with an acute demyelinating 
syndrome, at least one serum MOG- IgG1 
positive assay result, and a minimum of 12 
Strengths and limitations of this study
 ► This UK cohort study of myelin oligodendrocyte 
glycoprotein associated disease (MOGAD) includ-
ed 76 patients from England, Northern Ireland and 
Scotland.
 ► Prognostic factors associated with relapsing disease 
and time to first relapse were assessed using uni-
variable and multivariable modelling.
 ► The longitudinal impact of MOG antibody disappear-
ance on relapse risk was analysed using a Poisson 
regression model.
 ► A limitation of this study was the shorter duration 
of follow- up in monophasic patients with MOGAD.
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months follow- up were included. Serum MOG- IgG1 Abs 
were detected using a live cell- based assay employing full- 
length human MOG (α1 isoform; Oxford Autoimmune 
Neurology Group).9
Demographic, clinical details of attacks, cerebro-
spinal fluid and MRI results, treatment and longitudinal 
MOG- Ab results were collected. Childhood onset was 
defined as disease onset at age <16 years. Patients were 
considered ‘monophasic’ if no relapses were observed 
after the first clinical attack for the duration of follow- up 
(at least 12 months) and were compared with relapsing 
patients with MOGAD. Patients where the diagnosis 
was made shortly after onset (<6 months) and prior to 
relapse were designated as ‘incident’ cases. The following 
outcomes were examined: (1) relapse at any time, (2) 
visual acuity <6/36 (one or both eyes at last follow- up), 
(3) time between first and second attack and (4) impact 
of MOG- Ab serostatus on relapse frequency.
Statistical analysis
Continuous covariates are summarised as median (IQR) 
unless otherwise stated with categorical covariates 
summarised as frequencies with associated percentages. 
For comparisons of covariates across groups, Fisher’s 
exact tests and Mann- Whitney U tests were applied for 
categorical and continuous data, respectively.
To evaluate the impact of covariates on each endpoint, 
univariable and multivariable modelling were applied. 
Multivariable models for binary endpoints were 
constructed using a generalised linear model assuming 
a binomial distribution and a logistic link function and 
using a forward stepwise approach. Model evaluations 
were performed using Akaike Information Criterion. 
Model performance were assessed by comparing the 
linear predictors against the model outcome using 
receiver operating curve (ROC) and area under the curve 
(AUC). Model results are presented in terms of ORs with 
associated 95% CIs. For the time- to- event outcome, esti-
mates of the probability of relapse were obtained using 
the Kaplan- Meier method. Univariable and multivariable 
analyses were performed using Cox proportional hazards 
models with an equivalent procedure used to evaluate 
univariate models and construct multivariable models. 
Results are presented in terms of HRs with 95% CIs. The 
longitudinal impact of MOG- Ab negativity on patient 
relapse was investigated using a random effects Poisson 
regression model. Here, MOG- Ab negativity was included 
as a fixed effect and the time included in the model as a 
(log) offset. Patient identifier was included as a random 
effect. Results are presented as relative and absolute risk 
for observing a relapse with 95% CIs. A threshold of 
p<0.05 was applied for statistical significance. All analyses 
were performed using R (V.3).
Patient and public involvement
Clinical data from patients were included in this study. 
The development of the research question was driven by 
our patient’s uncertainty over future relapse risk following 
a first presentation of MOGAD. The patients and public 
were not explicitly involved the design or conduct of this 
study. Results will be disseminated at the NMOSD UK 




We identified 76 patients with MOGAD with a median 
onset age of 27 (IQR 19–45), 54% were female and 17% 
had disease onset in childhood (age <16 years). The 
geographic distribution of patients is shown in online 
supplemental figure 1. In total, 42 relapsing patients 
(total no of relapses=140) and 34 monophasic patients 
were identified. The median time from first clinical attack 
to diagnosis in the incident cohort (n=38) was 1 month 
(IQR 0–2 months). The clinical profile of patients and 
respective univariable analyses is presented in table 1 and 
online supplemental table 1.
Overall, there was a slight female predominance (54%) 
and although the proportion of male patients did not reach 
statistical significance in the univariable analysis, male sex 
was associated with a lower overall risk of relapsing disease 
(OR 0.16 95% CI 0.04 to 0.68; p=0.014) and time to first 
relapse (HR 0.46 95% CI 0.24 to 0.89; p=0.011) in multi-
variable analyses (figure 1, online supplemental table 2). 
The majority of patients (93%) were white; there were no 
racial differences between the groups. The median age 
of relapsing patients was lower than monophasic patients 
(26 (16–40) versus 37 (27–51) years; p=0.001). Develop-
ment of MOGAD after the age of 16 years was associated 
with a lower risk of relapsing disease in the multivariable 
analysis (OR 12.54 (1.81 to 87.17; p=0.011)), but 12/13 
children had relapses, suggesting a bias towards follow- up 
of children into adulthood with relapsing disease.
Clinical course
Relapsing disease was observed in 18% of incident cases 
and 55% of the total cohort with a median time to first 
relapse of 11.5 (IQR 3–46) months. A survival analysis 
for time to first relapse between the incident and total 
cohort is presented in online supplemental figure 2. 
The most common first clinical presentations were ON; 
61%, TM; 42% and bilateral ON (36%, table 1). TM 
and longitudinally extensive transverse myelitis (LETM) 
were more frequently part of the first clinical attack in 
monophasic patients (62% vs 26%, p=0.002% and 41% 
vs 17%; p=0.022, respectively). In multivariable analysis, 
TM with a first attack was associated with a lower overall 
risk of relapse (OR 0.03, 95% CI 0.004 to 0.23; p=0.001) 
and a longer time to first relapse (HR 0.42 95% CI 0.22 
to 0.82; p=0.011; figure 2 and online supplemental table 
2). Importantly although median follow- up duration was 
longer in relapsing as compared with monophasic patients 
(107 (44–162) vs 33.5 (20–56) months; p<0.001)), the 
median follow- up times of these groups of patients with 
TM specifically were similar (35 (26–62) vs 55 (43–113); 
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Table 1 Univariate analysis of relapsing and monophasic patients with myelin oligodendrocyte glycoprotein antibody 
associated disease
Relapsing=42 Monophasic=34 P value Incident cohort=38 Total cohort=76
Demographics (%)
Female (%) 64 (27/42) 41 (14/34) 0.064 47 (18/38) 54 (41/76)




Median onset age years 
(IQR)
26 (16–40) 37 (27–51) 0.001†* 37 (27–45) 27 (19–45)
Age <16 years at onset 29 (12/42) 3 (1/34) 0.004* 3 (1/38) 17 (13/76)
ADEM 12 (5/42) 0 (0/34) 0.061 3 (1/38) 7 (5/76)
ON 62 (26/42) 59 (20/34) 0.817 50 (19/38) 61 (46/76)
bON 31 (13/42) 41 (14/34) 0.470 32 (12/38) 36 (27/76)
TM 26 (11/42) 62 (21/34) 0.002* 58 (22/38) 42 (32/76)
LETM 17 (7/42) 41 (14/34) 0.022* 40 (15/38) 28 (21/76)
ON+TM 14 (6/42) 24 (8/34) 0.377 21 (8/38) 18 (14/76)
Brain involvement 29 (12/42) 21 (7/34) 0.595 29 (11/38) 25 (19/76)
>2 CNS sites 17 (7/42) 25 (12/34) 0.109 32 (12/38) 25 (19/76)
Infective trigger 8 (1/13) 40 (6/15) 0.084 35 (6/17) 25 (7/28)
EDSS>3 at nadir 83 (33/40) 91 (31/34) 0.326 92 (35/38) 87 (64/74)
EDSS>3 6 m 17 (7/41) 27 (9/34) 0.400 24 (9/38) 21 (16/75)
Treatment (IS) 67 (28/42) 91 (31/34) 0.013* 87 (33/38) 68 (59/76)
Steroids>1 m 37 (15/41) 76 (25/33) 0.001* 70 (26/37) 38 (40/74)
Steroids>3 m 32 (13/41) 55 (18/33) 0.060 49 (18/37) 35 (31/74)
Non- steroid IS 5 (2/42) 27 (7/33) 0.038* 19 (7/37) 12 (9/75)
Comparison % (n/
total)
Relapsing – – – 18 (7/38) 55 (42/76)
Relapse <12 m 52 (22/42) – – 86 (6/7) 29 (22/76)
>3 attacks 62 (26/42) – – 43 (3/7) 34 (26/76)
>4 attacks 43 (18/42) – – 1 (1/7) 24 (18/76)
Median ARR (range) 0.45 (0.07–5.43) – – 0.66 (0.18–2.04) 0.45 (0.07–5.43)
ADEM ever 15 (5/42) 0 (0/34) 0.061 3 (1/38) 7 (5/76)
ON ever 88 (37/42) 59 (20/34) 0.007* 55 (21/38) 75 (57/76)
bON ever 55 (23/42) 38 (13/34) 0.172 40 (15/38) 47 (36/76)
TM ever 52 (22/42) 62 (21/34) 0.488 61 (23/38) 57 (43/76)
LETM ever 29 (12/42) 38 (13/34) 0.064 40 (15/38) 33 (25/76)
ON+TM ever 50 (21/42) 27 (9/34) 0.058 26 (10/38) 39 (30/76)
Brain involvement ever 41 (17/42) 24 (8/34) 0.150 32 (12/38) 33 (25/76)
>1 CNS site ever 67 (28/42) 41 (14/34) 0.597 45 (17/38) 55 (42/76)
Other Abs present (eg, 
ANA, ENA)
16 (6/38) 18 (5/28) 1.00 19 (6/32) 17 (11/66)
MRI brain abnormality 50 (20/40) 44 (15/34) 0.647 47 (18/38) 47 (35/74)
MRI spine abnormality 56 (23/41) 69 (20/29) 0.325 67 (22/33) 61 (43/70)
CSF protein median 
(range)
0.47 (0.18–2.27) 0.44 (0.16–1.66) 0.954† 0.43 (0.16–1.66) 0.45 (0.16–2.27)
CSF WCC median 
(range)
2.5 (0–550) 30 (0–937) 0.008†* 25 (0–937) 10 (0–937)
Unmatched oligoclonal 
bands
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p=0.11). In addition, there was no difference in use of 
steroids>1 m in those patients presenting with or without 
TM (59% vs 50%; p=0.485).
Simultaneous ON+TM at any point was associated 
with a greater risk of relapsing disease (OR 12.54 (1.81 
to 87.17); p=0.011), but follow- up duration was shorter 
in these patients with monophasic disease (p=0.018). 
The proportion of patients presenting with bilateral ON 
and multi- CNS site involvement were similar between 
relapsing and monophasic groups. Three patients 
presented with encephalitis and seizures, all of whom 
had a relapsing disease course. Expanded disability status 
score (EDSS) at nadir and 6 months after first attack was 
similar in monophasic and relapsing patients. Preceding 
infective symptoms were more frequent in monophasic 
patients, but the results did not reach statistical signifi-
cance (40% vs 8%; p=0.084).
Overall, more than 2 and 3 attacks were observed in 34% 
(26/76) and 24% (18/76) of patients, respectively. Only 
18% of incident cases relapsed and 86% of first relapses 
occurred within 12 months of the first attack. Follow- up 
duration was shorter in the incident cohort as reflected 
Relapsing=42 Monophasic=34 P value Incident cohort=38 Total cohort=76
At follow- up % (n/
total)
VA <6/36 in at least one 
eye at fu
30 (12/40) 3 (1/34) 0.002* 3 (1/37) 18 (13/74)
EDSS>4 at last FU 22 (9/41) 15 (5/34) 0.555 16 (6/38) 19 14/75)
EDSS>3 at last FU 44 (18/41) 21 (7/34) 0.049* 24 (9/38) 33 (25/75)
Bladder dysfunction 32 (13/41) 33 (11/34) 1.00 34 (13/38) 32 (24/75)
Urinary catheter use 15 (6/41) 21 (7/33) 0.545 19 (7/37) 18 (13/74)
Bowel dysfunction 12 (5/41) 29 (10/34) 0.084 26 (10/38) 20 (15/75)
Erectile dysfunction 7 (1/14) 32 (6/19) 0.195 30 (6/20) 21 (7/33)
Current smoker 26 (9/35) 4 (1/27) 0.030* 9 (3/32) 16 (10/62)
Median FU/months 
(IQR)




0 (0/42) 6 (2/34) 0.197 5 (2/38) 3 (2/76)
Prednisolone +other IS 36 (15/42) 6 (2/34) 0.002* 13 (5/38) 22 (17/76)
Azathioprine 12 (5/42) 3 (1/34) 0.216 3 (1/38) 8 (6/76)
Mycophenolate mofetil 33 (14/42) 9 (3/34) 0.013 18 (7/38) 22 (17/76)
Rituximab 7 (3/42) 0 (0/34) 0.248 0 (0/38) 4 (3/76)
IVIg 10 (4/42) 0 (0/34) 0.123 0 (0/38) 5 (4/76)
Tocilizumab 2 (1/42) 0 (0/34) 1.00 0 (0/38) 1 (1/76)
No IS 21 (16/42) 82 (28/34) <0.001* 74 (28/38) 58 (44/76)
MOG- Ab
No of patients MOG- 
Ab(+) at last review
62 (24/39) 47 (15/32) 0.229 51 (19/37) 55 (39/71)
Median no of samples 
(IQR)
4 (3–6) 3 (2–5.5) 0.407† 3 (3–6) 3 (3–6)
Median time between 
first and last sample/
months (IQR)
30 (15.8–43.3) 29.5 (6.3–47) 0.782† 28 (6.5–46.5) 30 (15–46)
Median time to MOG- 
IgG(-) months (IQR)
103 (30.3–132) 12 (6–50) 0.003†* 11 (7–33) 34 (9–96)
Relapses (within 6 
months) of MOG- Ab 
negative
2 (1/42) – – 14 (1/7) 1 (1/76)
*P<0.05.
†Mann- Whitney U test.
Abs, antibodies; ADEM, acute disseminated encephalomyelitis; ANA, antinuclear antibody; ARR, annualised relapse rate; bON, bilateral ON; CNS, 
central nervous system; CSF, cerebrospinal fluid; EDSS, expanded disability status score; ENA, extractable nuclear antigen ; FU, follow- up; IS, 
immunosuppression; IVIg, intravenous immunoglobulin; LETM, longitudinally extensive TM; ON, optic neuritis; TM, transverse myelitis; VA, visual 
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in the higher annualised relapse rate (ARR) in these 
patients as compared with the total cohort (0.66 (0.18–
2.04) vs 0.45 (0.07–5.43)). Smoking was more frequently 
noted at follow- up in relapsing patients (26% vs 4%; 
p=0.030) but median ARR in smokers was similar to non- 
smokers in the incident patients with MOGAD (p=0.533). 
The most common CNS sites involved in attacks were 
the optic nerve (57/76; 75%), spinal cord (43/76; 57%) 
or simultaneous involvement of both these sites (30/76; 
39%). The site of CNS involvement was similar between 
relapsing and monophasic groups with the exception of 
ON, which was more common in relapsing patients (88% 
vs 59%; p=0.007).
Paraclinical tests
In the total cohort, MRI abnormalities in brain and spine 
were observed in 47% and 61% of cases, respectively. The 
frequency of abnormalities on MRI brain (p=0.647) and 
spinal cord (p=0.325) were similar between relapsing and 
monophasic patients. CSF white cell count was higher in 
monophasic patients (p=0.008). Unmatched oligoclonal 
bands were seen in only 3/45 (7%) cases tested. Non- 
organ specific autoantibodies (eg, antinuclear antigen, 
extractable nuclear antigen) were present in 16% of 
relapsing and 18% and monophasic patients. None of 
these variables maintained a significant association in 
multivariable analysis.
Treatment
Overall, 38% (40/74) of patients received steroid treat-
ment for >1 month and 12% (9/75) were commenced 
on non- steroid immunosuppression (IS) following the 
onset clinical attack. Both steroid treatment for >1 month 
(76% vs 37%; p=0.001) and non- steroid IS (27% vs 5%; 
p=0.038) were associated with monophasic disease. In 
multivariable analysis, treatment of the first attack with 
steroids>1 month was associated with a lower overall 
relapse risk (OR 0.2, 95% CI 0.05 to 0.80; p=0.022, online 
supplemental table 2). In keeping with current UK prac-
tice, steroids >1 m were more frequently used in incident 
as compared with non- incident patients (70% vs 39%). 
Overall, 32/76 (42%) of patients with MOGAD received 
long term IS, and of these patients 26 (81%) had relapsing 
disease. In order of frequency, the most commonly used 
non- steroid immunosuppressants were mycopheno-
late mofetil (22%) and azathioprine (8%). Intravenous 
immunoglobulin (IVIg) (5%), rituximab (4%) and tocili-
zumab (1%) were used as second- line and third- line 
therapies. In 22% of patients, maintenance prednisolone 
(5–15 mg/day) was combined with non- steroid IS.
An evaluation of the multivariable model to describe 
monophasic patients was performed using ROC analysis 
with the following factors—age >16 years, male sex, TM at 
onset, steroids >1 month. Using the linear predictor from 
the fitted model, an AUC of 0.92 was achieved. However, 
in view of the observer bias relating to age at disease 
onset, this variable was removed and a high AUC of 0.85 
was maintained.
Long-term outcome
Poor visual outcome defined by a visual acuity of <6/36 
in at least one eye at last review was observed in 18% 
(13/74) of patients after a median of 13.5 years follow- up 
(online supplemental table 1). Of those with poor visual 
outcome, 85% (11/13) had an EDSS >3% and 39% 
(5/13) had an EDSS >4. Permanent visual disability (VA) 
was more common in relapsing MOGAD (30% vs 3%; 
p=0.002) and median follow- up duration in these patients 
was longer (median 161 vs 43 months; p<0.0001). Interest-
ingly patients presenting with TM or LETM at first attack 
were less likely to develop optic nerve involvement (53% 
vs 91%; p=0.0003% and 38% vs 89%; p=0.0001, respec-
tively) and had a better visual prognosis (49% vs 8%; 
p=0.006% and 33% vs 0%; p=0.015, respectively, online 
supplemental table 1). In the multivariable analysis, TM 
with the first MOGAD clinical attack was associated with 
a favourable visual prognosis (OR 0.09 (0.01 to 0.70); 
p=0.022, online supplemental table 2). To determine 
whether this simply reflected less optic nerve involve-
ment in patients with TM at onset we analysed onset TM 
patients with subsequent ON attacks (17/32; 53%) and 
the remaining patients that developed ON only after first 
Figure 1 Kaplan- Meier analysis of relapse probability and 
sex.
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attack (12/30; 40%). Although the results were not signif-
icant, there was a trend towards better visual outcome 
in patients that presented with TM and had subsequent 
optic nerve involvement (6% vs 36%; p=0.06).
Patients with relapsing disease (92% vs 46%; p=0.002), 
>3 relapses (83% vs 29%; p=0.002) or a history of bilateral 
ON (77% vs 43%; p=0.033) had worse visual outcomes 
but these factors and others (MOG- Ab seronegative status 
and long term IS) did not maintain a significant associa-
tion in multivariable analysis. A visual acuity <6/36 in at 
least one eye at last review was more frequently observed 
with childhood onset MOGAD (46% vs 12%; p=0.008). 
As with findings related to higher relapse rate, this obser-
vation likely relates to preferential follow- up of children 
with more severe disease.
An EDSS >3 was recorded in 33% (25/76) of patients at 
last review after a median of 6.6 years follow- up. Follow- up 
duration was longer in patients with an EDSS >3 (median 
79 vs 44 months; p=0.004). Approximately a third of 
relapsing and monophasic patients had bladder dysfunc-
tion at last review. Rates of bowel and erectile dysfunc-
tion were not significantly different between relapsing 
and monophasic patients. Patients who received IVIg 
had worse EDSS (and visual) scores at follow- up due to 
refractory relapsing clinical disease with severe disability 
prior to treatment commencement. No clinical feature 
was associated with overall disability (EDSS >3) in multi-
variable analysis.
MOG-Ab serostatus
In total, 71 patients had more than 1 serum sample 
for MOG- Ab testing (table 1). The median number of 
samples in relapsing and monophasic groups (4 (IQR: 
3–6) vs 3 (IQR: 2–5.5); p=0.407) and patients with and 
without persistent MOG- Abs (3 (IQR: 3–6) vs 4 (IQR: 
3–6); p=0.563) were similar (online supplemental tables 1 
and 2). The median time between first and last sampling 
(30 (15.8–43.3) vs 29.5 (21–53.8) months; p=0.782) was 
also similar.
Persistent MOG- Ab detection was observed in 55% 
(39/71) of patients. In 2 patients MOG- Ab serostatus was 
initially negative and then became positive. In 5 patients, 
a fluctuating MOG- Ab serostatus was noted—following 
a positive MOG- Ab result 3 patients became transiently 
negative and then persistently positive and 2 patients 
became negative, positive and then persistently nega-
tive. The median time to negative MOG- Ab serostatus 
was 34 (9–96) months and as expected was shorter in the 
incident cohort (11 (7–33) months). The time interval 
was also shorter in the monophasic as compared with 
relapsing patient group (12 (6–50) vs 103 (30.3–132) 
months; p=0.003). Relapse within 6 months of a nega-
tive MOG- Ab assay was recorded in only 1 patient. Two 
further patients had a relapse after a negative result, but 
MOG- Ab testing was done more than 6 months prior to 
attack and undetected MOG- Ab positive seroconversion 
could not be excluded. Figure 3 summarises the longi-
tudinal MOG- Ab serostatus in relation to clinical attacks.
To assess the impact of MOG- Ab serostatus on clinical 
course we first analysed the risk of relapsing disease in 
those patients who became seronegative. Patients that 
became MOG- Ab seronegative were just as likely to have 
had relapsing disease as those who remained MOG- Ab 
positive (45% vs 62%; p=0.229). To determine if longitu-
dinal MOG- Ab serostatus influenced relapse rate we used 
a random effects Poisson regression model. The monthly 
risk of relapse was approximately 4% and reduced to 
0.5% following MOG- Ab negative seroconversion (RR 
0.11 (0.048–0.259); p<0.001, online supplemental table 
3). Figure 2 illustrates clinical course of patients in rela-
tion to longitudinal MOG- Ab serostatus. Unfortunately, 
it was not possible to assess the impact of MOG- Ab titre 
on risk of relapsing and monophasic disease as these data 
were not available in all patients.
In univariable analysis, patients were more likely to 
become MOG- Ab negative if they presented with TM 
(p=0.018), had an infective trigger (p=0.041), or had 
less three attacks (p=0.039) overall (online supplemental 
table 1). A trend towards MOG- Ab negative seroconver-
sion was noted with long- term IS (72% vs 33%; p=0.057) 
but no specific treatment was associated with a higher like-
lihood of subsequent negative MOG- Ab serostatus. Longi-
tudinal MOG- Ab serostatus was not associated with overall 
disability (p=0.802) or VA (p=0.067). In the multivariable 
analysis, TM at onset was associated with MOG- Ab nega-
tive seroconversion (OR 2.85 (1.11 to 7.30); p=0.029).
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DISCUSSION
In this study that included MOGAD cases from across the 
UK, we found that male patients receiving >1 month of 
steroid treatment at disease onset and spinal cord involve-
ment at first presentation had a lower risk of relapsing 
disease. A transition to MOG- antibody negative serostatus 
occurred in around half of patients and was associated with 
a lower risk of relapse. Spinal cord involvement at onset 
was associated with negative MOG- Ab seroconversion.
There is wide variation in the reported rates of relapsing 
MOGAD in retrospective cohorts (27%–80%).1–5 Unsur-
prisingly, the highest proportion of relapsing disease 
has been observed in studies with longer follow- up dura-
tion. The stratification of relapse risk at disease onset is 
important when considering the long- term approach to 
MOGAD treatment. In this study, we analysed relapsing 
and monophasic patients to identify prognostic factors 
related to relapse and disability. We also included an inci-
dent cohort analysis to assess for observer bias.
The clinical characteristics of these patients with 
MOGAD were similar to previous reports, with relapsing 
disease observed in 55% of cases.1–6 10 A relapse rate of 
18% in incident cases was lower than other reported 
studies (27%–36%).1 2 6 It has been shown previously that 
the risk of relapse is highest in the first year and in this 
study only cases with at least 12 months follow- up were 
included.1 Furthermore, the median follow- up duration 
of incident cases was almost 3 years though it is note-
worthy that the risk of relapse in one study was 45% at 2 
years and 62% at 5 years.2
We found that in male patients the time to first relapse 
was longer and the overall risk of relapsing disease was 
lower. This is similar to the findings of a recent large 
French study in childhood onset MOGAD.6 The expla-
nation for this finding is uncertain, particularly as unlike 
other autoimmune diseases such as NMOSD, the female 
predominance in MOGAD is less marked.7 In our cohort 
patients presenting with spinal cord involvement at 
disease onset had a lower risk of relapsing disease and 
a longer latency to first relapse, reproducing findings 
from an Indian cohort study.5 Importantly, relapsing 
and monophasic patients with spinal cord involvement 
at disease onset were treated similarly with regards to 
steroid taper and had similar disease duration. As has 
been previously reported, a prolonged steroid taper with 
a first MOGAD attack was associated with a lower risk of 
relapsing disease.1 5 10 In keeping with UK recommenda-
tions for MOGAD treatment, a prolonged steroid taper 
was more frequently observed in the incident cases.11 As 
mentioned previously, these cases were followed for a 
median of 3 years and the lower relapse rates (18%) in 
this cohort may relate to the use of corticosteroids but 
also to disease duration. Paradoxically and in contrast to 
the findings by Cobo- Calvo et al, childhood onset disease 
was associated with relapsing disease and disability.6 This 
finding is explained by the preferential follow- up of 
children with more severe MOGAD who transition into 
adult neurological services. Accordingly, this parameter 
was excluded from the ROC analysis but a high AUC of 
0.85 was maintained for predicting patients less likely to 
develop relapsing disease using features identifiable at 
first clinical presentation (male sex, spinal cord involve-
ment, steroids >1 month).
VA <6/36 in at least one eye was observed in 17% of 
the total cohort, comparable to rates of 13% and 17% 
from other studies.1 6 In the multivariable analysis, spinal 
cord onset was associated with a better visual prognosis 
at follow- up. This relates to less optic nerve involvement 
in these cases but there was also a trend towards better 
visual outcome in patients presenting with TM with subse-
quent optic nerve involvement. Further exploration of 
this finding in a larger dataset would be of interest. Spinal 
cord involvement in MOGAD is frequently associated with 
residual bladder, bowel and erectile dysfunction and the 
former was present in around a third of patients in this 
study.1 12 As expected, in the univariable analysis TM was 
also associated with an EDSS >3 at long- term follow- up. 
Comparable to the 33% and 24% of patients presented 
here, 27% of a total MOGAD cohort and 22% of an inci-
dent cohort had an EDSS >3 in 2 large French studies.2 6 
Several factors of interest were identified in univariable 
but not multivariable analyses of VA (relapsing disease, 
number of relapses, and a history of bilateral ON) and 
overall disability (number of relapses and spinal cord 
involvement) that could be explored further.
In this study, we were able to analyse the longitudinal 
profile of patients in relation to MOG- Ab serostatus. 
MOG- Abs became negative in 45% of cases which is higher 
than rates reported in other studies of MOGAD, partic-
ularly adults (28%–57%).1 6 13 This finding may relate 
to longer follow- up times; the median time to negative 
serostatus in this study was almost 3 years. Although final 
MOG- Ab serostatus was not associated with a relapsing 
disease course, longitudinal analysis of serostatus showed 
a reduction of 4%–0.5% in monthly relapse risk with 
MOG- Ab negative serostatus. Only 1 patient relapsed 
within 6 months of a negative MOG- Ab assay. These 
findings support the prognostic value of serial antibody 
testing and consideration of MOG- Ab serostatus in long 
term treatment decisions.
This study benefited from a nationwide catchment 
of patients across the UK that were followed in a single 
centre but is not without limitation. As with previous 
studies, higher relapse rates were observed in the total 
cohort as compared with incident cases. In particular, 
childhood onset patients had higher rates of disability 
with longer follow- up duration due to follow- up bias. 
Monophasic patients were followed for a median of 3 
years which is longer than the median time of 15.8 months 
to first relapse in a nationwide French study.2 However, 
relapsing patients had a longer duration of follow- up as 
compared with monophasic cases. With a larger incident 
cohort, a separate analysis could have been performed to 
address this. However, prognostic factors related to male 
sex, onset attack topography, onset attack treatment and 
MOG- Ab serostatus were less likely to be influenced by 
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these differences and are the key findings of this study. 
Importantly subgroup analyses were performed to assess 
for the impact of differences in disease duration and 
were factored into data interpretation. In this study we 
defined MOGAD on the basis of serum MOG- Abs rather 
than serum and CSF. Intrathecal synthesis of MOG- Ab 
has been reported and it would be interesting to explore 
this further in a prospective study that includes CSF 
analysis.14 In a specialised centre referral bias towards 
a more severe relapsing disease is also a likely factor, 
though similar numbers of relapsing and monophasic 
patients were present overall making group compari-
sons possible. As with all observational studies the results 
of the analyses do not hold the same weight as those of 
randomised controlled studies. In particular, for the anal-
ysis of observational datasets, the onus is on accounting 
for possible confounding when drawing conclusions on 
possible causal effects. While multivariable modelling is a 
powerful tool in adjudging for possible confounding, the 
impact of conclusions is given further weight by external 
validation against a new dataset and will be the focus of 
future research.
In summary, we have identified that male patients with 
spinal cord involvement at disease onset have a lower risk 
of relapsing disease and longer latency to first relapse. 
Steroid treatment for at least 1 month at disease onset 
was also associated with a monophasic disease course. 
MOG- Ab negative seroconversion was associated with a 
lower risk of relapse and may help inform treatment deci-
sions and duration.
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Demographics % (n/total)   
Female (%) 54 (7/13)  53 (32/61) 1 60 (15/25) 62 (25/50) 0.468 54 (21/39) 56 (18/32) 1.00 
White (%) 100 (13/13) 92 (56/61) 0.579 96 (24/25) 92 (46/50) 0.659 90 (35/39) 97 (31/32) 0.370 
1st attack characteristics % (n/total)   
Median onset age years (IQR) 24 (11-38) 33 (20-45) 0.031† 29 (16-51) 30 (23-41) 0.948† 29 (17-44) 29 (19-47) 0.985† 
Age<16yrs at onset 46 (6/13) 12 (7/61) 0.008* 32 (8/25) 10 (5/50) 0.025* 15 (6/39) 22 (7/32) 0.547 
ADEM 15 (2/13) 5 (3/58) 0.210 4 (1/25) 8 (4/50) 0.659 8 (3/39) 6 (2/32) 0.168 
ON  69 (9/13) 51 (36/61) 0.550 52 (13/25) 64 (32/50) 0.331 64 (25/39) 50 (16/32) 0.334 
bON  46 (6/13) 34 (21/61) 0.530 32 (8/25) 38 (19/50) 0.799 44 (17/39) 22 (7/32) 0.078 
TM  8 (1/13) 49 (30/61) 0.006* 40 (10/25) 42 (21/50) 1.00 31 (12/39) 59 (19/32) 0.018* 
LETM  0 (0/13) 33 (20/61) 0.015* 32 (8/25) 24 (12/50) 0.581 21 (8/39) 38 (12/32) 0.184 
ON+TM 8 (1/13) 20 (12/61) 0.442 8 (2/25) 22 (11/50) 0.198 15 (6/39) 22 7/32) 0.547 
Brain involvement 31 (4/13) 23 (14/61) 0.722 32 (8/25) 26 (13/50) 0.596 31 (12/39) 22 (7/32) 0.433 
>2 CNS sites  15 (2/13) 26 (16/61) 1.00 20 (5/25) 26 (13/50) 0.775 21 (8/39) 29 (9/32) 0.578 
Infective trigger  0 (0/3) 44 (7/16) 0.540 25 (2/8) 26 (5/19) 1.00 15 (2/13) 62 (8/13) 0.041* 
EDSS>4 at nadir  46 (6/13) 53 (32/61) 0.765 67 (16/24) 46 (23/50) 0.220 55 (21/38) 56 (18/32) 1.00 
EDSS>4 6m  15 (2/13) 15 (9/61) 1.00 40 (10/25) 2 (1/50) - 13 (5/39) 16 (5/32) 0.460 
Treatment  69 (9/13) 80 (49/61) 0.460 84 (21/25) 74 (37/50) 0.393 74 (29/39) 84 (27/32) 1.00 
Steroids>1m  27 (3/11) 61 (37/61) 0.052 52 (13/25) 55 (27/49) 1.00 55 (21/38) 53 (17/32) 1.00 
Steroids>3m  27 (3/11) 46 (28/61) 0.331 52 (13/25) 37 (18/49) 0.225 40 (15/38) 44 (14/32) 0.809 
non-steroid IS 8 (1/13) 13 (8/60) 1.00 16 (4/25) 10 (5/49) 0.470 8 (3/39) 19 (6/32) 0.282 
Comparison % (n/total)   
Relapsing  92 (12/13) 46 (28/61) 0.002* 72 (18/25) 46 (23/50) 0.049* 62 (24/39) 44 (14/32) 0.157 
Relapse<12m 33 (4/12) 57 (16/28) 0.301 28 (7/25) 28 (14/50) 1.00 63 (15/24) 36 (5/14) 0.179 
>3 attacks 83 (10/12) 57 (16/28) 0.157 52 (13/25) 26 (13/50) 0.039* 71 (17/24) 50 (7/14) 0.298 
>4 attacks  83 (10/12) 29 (8/28) 0.002* 67 (12/18) 12 (6/50) 0.0001* 50 (12/24) 14 (2/14) 0.039* 











ADEM ever 15 (2/13) 5 (3/61) 0.210 4 (1/25) 8 (4/50) 0.659 8 (3/39) 6 (2/32) 1.00 
ON ever 100 (13/13) 69 (42/61) 0.059 72 (18/25) 76 (38/50) 0.781 74 (29/39) 72 (23/32) 1.00 
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bON ever 77 (10/13) 43 (26/61) 0.033* 52 (13/25) 46 (23/50) 0.634 54 (21/39) 34 (11/32) 0.150 
TM ever 62 (8/13) 56 (34/61) 0.766 77 (19/25) 46 (23/50) 0.015* 54 (21/39) 66 (21/32) 0.343 
LETM ever 15 (2/13) 36 (22/61) 0.201 44 (11/25) 26 (13/50) 0.126 31 (12/39) 28 (12/32) 0.619 
ON+TM ever 62 (8/13) 34 (21/61) 0.116 48 (12/25) 34 (17/50) 0.316 41 (16/39) 41 (13/32) 1.00 
Brain involvement ever 46 (6/13) 30 (18/61) 0.329 32 (8/25) 34 (17/50) 1.00 44 (17/39) 25 (8/32) 0.136 
>1 CNS site ever 77 (10/13)  49 (30/61) 0.123 64 (16/25) 50 (25/50) 0.327 62 (24/39) 53 (17/32) 0.630 
Other Abs present (e.g., ANA, ENA) 30 (3/10) 14 (8/56) 0.351 16 (4/25) 17 (7/42) 1.00 21 (7/33) 10 (3/30) 0.308 
MRI brain abnormality 54 (7/13) 47 (28/60) 0.763 48 (12/25) 47 (23/49) 1.00 55 (21/38) 41 (13/32) 0.241 
MRI spine abnormality  69 (9/13) 61 (34/56) 0.753 76 (19/25) 53 (24/45) 0.098 63 (22/35) 68 (21/31) 0.797 











CSF WBC median (range) 1 (0-4) 22 (0-937) 0.059† 4 (0-937) 23 (0-550) 0.020†* 10 (0-937) 8.5 (0-221) 0.959† 
Unmatched oligoclonal bands  0 (0/6) 8 (3/39) 1.00 6 (1/25) 4 (2/50) 1.00 8 (2/20) 4 (1/24) 0.58 
At follow-up % (n/total)   
VA<6/36 in at least one eye at fu - - - 44 (11/25) 4 (2/49) 0.0001* 21 (8/39) 3 (1/30) 0.067 
EDSS>4 at fu 39 (5/13) 16 (10/61) 0.122 58 (14/25) - - 21 (8/39) 19 (6/32) 1.00 
EDSS>3 at fu 85 (11/13) 23 (14/61) <0.0001* - - - 31 (12/39) 34 (11/32) 0.802 
Bladder dysfunction 31 (4/13) 31 (19/61) 1.00 56 (14/25) 20 (10/50) 0.003* 26 (10/39) 44 (14/32) 0.134 
Urinary catheter use 23 (3/13) 17 (10/60) 0.690 48 (12/25) 2 (1/49) 0.0001* 13 (5/39) 25 (8/32) 0.227 
Bowel dysfunction 8 (1/13) 23 (14/61) 1.00 40 (10/25) 10 (5/50) 0.005* 18 (7/39) 28 (9/32) 0.395 
Erectile dysfunction 0 (0/6) 26 (7/27) 0.301 22 (2/9) 21 (5/24) 1.00 12 (2/17) 36 (5/14) 0.198 
Current smoker 29 (2/7) 15 (8/53) 0.330 19 (4/21) 15 (6/41) 0.722 15 (5/33) 14 (4/28) 1.00 
Median f/u duration months (IQR) 
161 (95-
212) 
43 (23-75) <0.0001†* 79 (41-194) 44 (23-77) 0.004†* 49 (21-113) 53 (34-115) 0.275† 
Treatment % (n/total)   
Prednisolone monotherapy 0 (0/13) 3 (2/61) 1.00 4 (1/25) 2 (1/50) 1.00 3 (1/39) 3 (1/32) 1.00 
Prednisolone + other IS 46 (6/13) 18 (11/61) 0.063 32 (8/25) 18 (9/50) 0.242 28 (11/39) 16 (5/32) 0.260 
Azathioprine 8 (1/13) 8 (5/61) 1.00 4 (1/25) 10 (5/50) 0.657 10 (4/39) 6 (2/32) 0.684 
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Supplementary table 1. Univariate analysis of visual outcome, overall disability, and MOG-Ab serostatus. VA; visual acuity, MOG-Ab; myelin oligodendrocyte glycoprotein antibodies, ADEM; acute disseminated 
encephalomyelitis, ON; optic neuritis, bON; bilateral ON, TM; transverse myelitis,  LETM; longitudinally extensive TM, CNS; central nervous system, EDSS; expanded disability status score, IS; immunosuppression, 
ARR; annualised relapse rate, NMOSD; neuromyelitis optica spectrum disorder, IPND; international panel for NMOSD diagnosis, Abs; antibodies, IVIg; intravenous immunoglobulin, †; Mann-Whitney U test, *; p<0.05.       
Mycophenolate mofetil 39 (5/13) 20 (12/61) 0.160 32 (8/25) 18 (9/50) 0.242 26 (10/39) 13 (4/32) 0.234 
Rituximab 15 (2/13) 2 (1/61) 0.078 8 (2/25) 2 (1/50) 0.256 5 (2/39) 6 (2/32) 1.00 
IVIg 15 (2/13) 0 (0/61) 0.029* 16 (4/25) 0 (0/50) 0.010* 10 (4/39) 0 (0/39) 0.115 
Tocilizumab 0 (0/13) 2 (1/61) 1.00 0 (0/25) 2 (1/50) 1.00 3 (1/39) 0 (0/32) 1.00 
No IS 23 (3/13) 66 (40/61) 0.011* 44 (11/25) 66 (33/50) 0.198 33 (19/39) 72 (23/32) 0.057 
MOG-Ab    
No of patients MOG-Ab(+) at last review 11 (1/13) 48 (29/60) 0.011* 48 (11/23) 44 (21/48) 0.802 - -   
Median no of samples (IQR) 3 (1.3-3.8) 4 (3-6) 0.03† 3.5 (2.3-5) 3 (2.8-6) 0.799† 3 (3-6) 4 (3-6) 0.563† 
Median time between 1st and last sample (IQR)/months 36 (18-65) 
29.5 (15.3-
45.5) 
0.193† 35 (19-47) 28 (7.8-43.8) 0.283† 29 (10-40) 29.5 (21-53.8) 0.174† 
Median time to MOG-IgG(-) months (IQR) 48*  34 (9.5-103) - 48 (14-132) 34 (7-103) 0.293† - 38 (9.3-106.5) - 
Relapses whilst MOG-Ab negative 0 (0/1) 7 (2/29) 1.00 9 (1/11) 5 (1/21) 1.00 - 3 (1/32) - 
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  Relapse (any time) VA≤6/36 Time between 1st and 2nd Attack 
  est (se) 
Odds ratio 
(95% CI) 
P-value est (se) 
Odds ratio 
(95% CI) 




(Intercept) 5.26 (1.5) - <0.001* -0.95 (0.34)   - 0.005* - - - 
Steroids 1m -1.59 (0.695) 
0.2  
(0.05, 0.80) 
0.022* -  - - - - - 
TM w/ 1st attack -3.51 (1.032) 
0.03  
(0.00, 0.23) 
0.001* -2.45 (1.072)  
0.09  
(0.01, 0.70)  
0.022* -0.86 (0.34) 0.42 (0.22, 0.82) 0.011* 
Age  -0.08 (0.028) 
0.93  
(0.88, 0.98) 
0.005*  - - - - - - 
ON/TM 2.53 (0.989) 
12.54  
(1.81, 87.17) 
0.011*  - - - - - - 
SexM -1.86 (0.754) 
0.16  
(0.04, 0.68) 
0.014*  - - - -0.78 (0.34)  0.46 (0.24, 0.89) 0.011* 
AUC  -  0.98  -  - - - - - - 
Supplementary table 2. Multivariable and ROC analysis. VA; visual acuity, CI; confidence interval, m; month, ON; optic neuritis, TM; transverse myelitis, M; male, AUC; area under the curve, *; p<0.05. 
 
 




 Est (se) RR (95% CI) P-value 
(Intercept) -3.3 (0.175) 0.04 (0.026-0.052 <0.001* 
MOG-Ab negativity  -2.19 (0.429) 0.11 (0.048-0.259 <0.001* 
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